Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Policy / Regulatory

GenScript Shares Slide on US Congressional Request for FBI Investigation

Fineline Cube Jun 3, 2024

Shares of GenScript Biotechnology Co., Ltd (HKG: 1548), a China-based Contract Development and Manufacturing Organization...

Company Drug

Pfizer’s Lorbrena Outperforms Xalkori in 5-Year ALK-Positive NSCLC Follow-Up

Fineline Cube Jun 3, 2024

Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase...

Company Drug

Astellas Resubmits FDA Application for Vyloy as Treatment for CLDN18.2-Positive Cancer

Fineline Cube Jun 3, 2024

Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has resubmitted its first-in-class anti-CLDN18.2 biologic...

Company Drug

Simcere Pharma’s Suvemcitug Shows Positive Results in Platinum-Resistant Ovarian Cancer Study

Fineline Cube Jun 3, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has presented updated data...

Company Drug

Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...

Company Drug

Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024

Fineline Cube Jun 3, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...

Policy / Regulatory

NMPA Announces Digitalization of Medical Device Regulatory Documents

Fineline Cube Jun 3, 2024

The National Medical Products Administration (NMPA) has announced a transition to digitalize regulatory documentation for...

Policy / Regulatory

China’s NHSA Launches New Procedures for Drug Catalogue Attribution Identification

Fineline Cube Jun 3, 2024

The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and...

Company Drug

Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024

Fineline Cube Jun 3, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...

Company Medical Device

Andon Health’s COVID-19 Trio Test Kit and OTC Antigen Test Win FDA Approval

Fineline Cube Jun 3, 2024

Andon Health Co., Ltd (SHE: 002432), a healthcare company based in China, has announced that...

Company

Nanjing Kingfriend Biochemical Gets FDA Nod for Dacarbazine Manufacture at Sagent Facility

Fineline Cube Jun 3, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced that...

Company Drug

Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study

Fineline Cube Jun 3, 2024

Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...

Company Drug

Chipscreen’s Chidamide in Sight of Breakthrough Therapy Designation in China for MSS/pMMR Colorectal Cancer

Fineline Cube Jun 3, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Simcere Pharma’s Anti-Insomnia Drug Daridorexant Meets Primary Endpoint in Phase III Clinical Trial

Fineline Cube Jun 3, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced topline results from a Phase III...

Company Drug

ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of Timdarpacept in CMML

Fineline Cube Jun 3, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe

Fineline Cube Jun 3, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...

Company Deals

MSD to Acquire Ophthalmology Specialist Eyebiotech in a Deal Valued Up to USD 3 Billion

Fineline Cube May 31, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into an agreement to acquire UK-based...

Company Drug

FDA Extends Indication for BMS’ CAR-T Therapy Breyanzi to Include Relapsed MCL in Adults

Fineline Cube May 31, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Drug

Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market

Fineline Cube May 31, 2024

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...

Company Drug

Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain

Fineline Cube May 31, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Posts pagination

1 … 354 355 356 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.